Thousand Oaks-based biotech giant Amgen said repatriating earnings held overseas is likely to cost it between $6 billion and $6.5 billion in taxes. It did not say the net amount that would be transferred or at what rate it would be taxed. “The company expects to have access to its accumulated global cash as well…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
